Investor profile
Charlie Petty
Angel & Kauffman Fellow at Kauffman Fellows, Venture Partner at Global Health Investment, Co-Founder & Venture Partner at Adjuvant Capital, Science and technology investor at Stripe, Board Member - Stealth NewCo at Third Rock Ventures
An angel investor based in New York City, United States, Charlie Petty has 7 known investments: Excision BioTherapeutics, Digital Alloys, New Valence Robotics Corporation, Adcole Corporation, Just Appraised, Minervax ApS and Sèvis Finansye Fonkoze.
Is Charlie Petty a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
Contacts
Charlie Petty portfolio companies (7)
- Excision BioTherapeutics
- Digital Alloys
- New Valence Robotics Corporation
- Adcole Corporation
- Just Appraised
- Minervax ApS
- Sèvis Finansye Fonkoze
Affiliated funds' portfolios
Kauffman Fellow at Kauffman Fellows, whose known portfolio counts 5 companies
- Ligandal
- Catalog
- Flash
- Sidecar Health
- Elves
Venture Partner at Global Health Investment, whose known portfolio counts 6 companies
- Biolinq
- Antheia
- CytoVale
- Terrestrial Bio
- Prenosis
- Micron Biomedical
Co-Founder & Venture Partner at Adjuvant Capital, whose known portfolio counts 9 companies
- 54gene
- Memo Therapeutics
- Antiva Biosciences
- Codagenix
- LimmaTech Biologics
- Minervax
- Curevo
- InDevR
- VitriVax
Science and technology investor at Stripe, whose known portfolio counts 17 companies
- Ramp
- TrueLayer
- Stedi
- Kite
- Remark
- Clerk
- Circuit & Chisel
- Rowspace
- Badge
- CoPlane
- Vengo AI
- InCorp Chain
- and 5 more
Board Member - Stealth NewCo at Third Rock Ventures, whose known portfolio counts 11 companies
- Maze Therapeutics
- Terremoto Biosciences
- Corvia Medical
- Azalea Therapeutics
- Syremis Therapeutics
- ARTBIO
- Seaport Therapeutics
- Merida Biosciences
- Trace Neuroscience
- Marea Therapeutics
- Synnovation Therapeutics
Investor Profile
Founders in the listed sector Healthcare, and focus areas Bioinformatics, Biotech, Cellular Therapy and Diagnostics will recognize the pattern in this portfolio.
Charlie Petty appears in Series A and Series B rounds across the known deals.
Reviewing the investment history helps decide whether there is a realistic fit before reaching out.
Colleagues
Showing 20 of 251
John Collison
President
San Francisco, United States
Aadil Mamujee
Stablecoins
New York, United States
Konstantin Vinogradov
Fellow - Class 30
London, United Kingdom
Lucas Dickey
Day Zero Things
Seattle, United States
Parker Conrad
Member Board of Directors
San Francisco, United States
Steve S.
Angel Investor
Redmond, United States
Heather Hartnett
Affiliated
New York, United States
Amit Anand
Kauffman Fellow
Singapore
Ashley Mayer
Kauffman Fellows, Class 27
Brooklyn, United States
Francisco Tolmasky
CEO
San Francisco, United States
Erica Duignan Minnihan
Kauffman Fellow
New York City, United States
Omar Darwazah
Investor
New York, United States
Chris McCann
Kauffman Fellows - Class 30
San Francisco, United States
Stephen Marcus
Angel Investor
Los Angeles, United States
William Gaybrick
President, Technology and Business
San Francisco, United States
Antonia Rojas Eing
Kauffman Fellow, Class 25
Mexico City
Anne Hoffer
Loves to learn
Chicago, United States
Bedy Yang
Kauffman Fellow
San Francisco, United States
Luis X Barrios
Class 20
Mexico City
Thad Langford
Kauffman Fellow Class 22
Kansas City, United States
Similar investors
Showing 20 of 100
Todd Pietri
Managing Partner
New York City, United States
Bernie Rudnick
Co-Founder
Newark, United States
Jeffrey Kaditz
angel investor
Chris Jackson
angel investor and operator angel
New York, United States
Andrew Sandford
angel investor
Boston, United States
Robert Stein
angel investor
New York, United States
Barry Fidelman
angel investor
Waltham, United States
Carl Bradford Byers
Partner
Boston, United States
Paul Silber
Board of Advisors
United States
Adrian Parton Mbe
angel investor
Cambridge, United Kingdom
Matt Crawford
angel investor
Austin, United States
Barbara Lubash
angel investor
Orange County, United States
David Wiersma
angel investor
Tucson, United States
Nicholas Fulco
angel investor
New York, United States
Peter Buckland
angel investor and operator angel
San Francisco, United States
Josh Perfetto
angel investor and operator angel
San Francisco, United States
Dennis Purcell
Founder and Senior Advisor
New York, United States
Chris Leiter
Founder & General Partner
San Francisco, United States
Peter Verrillo
angel investor
Boston, United States
Andy Palmer
angel investor and operator angel
Cambridge, United States
Frequently asked questions
Who is Charlie Petty?
Charlie Petty is an angel investor based in New York City, United States with 7 known investments on file, among them Excision BioTherapeutics, Digital Alloys and New Valence Robotics Corporation. The sections above list the sectors, stages and firms attached to that record.
What does Charlie Petty invest in?
Listed sectors include Healthcare; listed focus areas include Bioinformatics, Biotech, Cellular Therapy and Diagnostics. Those tags come from the companies attached to this profile, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Charlie Petty invest at?
The known deals of Charlie Petty include Series A and Series B rounds. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Charlie Petty listed at?
Charlie Petty is listed as Science and technology investor at Stripe. 251 other people in the database share a firm with Charlie Petty.
How do I contact Charlie Petty?
An email address and a LinkedIn page are on file for Charlie Petty. The address stays masked on this page and is readable inside RaiseHunt after you create an account. The database holds no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal